• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4598324)   Today's Articles (1751)   Subscriber (49356)
Number Citation Analysis
126
Roux C, Briot K, Dumarcet N, Bourgoin M, Chapurlat R, Christin-Maitre S, Cortet B, Costagliola D, Diebolt V, Lacoin F, Letombe B, Oberlin F, Orcel P, Ravaud P, Seret P, Thomas T, Vogel JY, Barna A, Nouyrigat E, Veyries ML, Yoldjian I. Traitement médicamenteux de l’ostéoporose post-ménopausique. Presse Med 2006;35:1529-39. [PMID: 17028517 DOI: 10.1016/s0755-4982(06)74847-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]  Open
127
Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas 2006;55:278-87. [PMID: 16713143 DOI: 10.1016/j.maturitas.2006.04.012] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2006] [Revised: 04/04/2006] [Accepted: 04/11/2006] [Indexed: 11/29/2022]
128
Dodwell D, Wardley A, Johnston S. Postmenopausal advanced breast cancer: Options for therapy after tamoxifen and aromatase inhibitors. Breast 2006;15:584-94. [PMID: 16504510 DOI: 10.1016/j.breast.2006.01.007] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2005] [Revised: 01/11/2006] [Accepted: 01/12/2006] [Indexed: 11/22/2022]  Open
129
Roux C. Ostéoporose: un objectif prioritaire, réduire le nombre de fractures. Presse Med 2006;35:1527-8. [PMID: 17028516 DOI: 10.1016/s0755-4982(06)74846-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]  Open
130
Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S. Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk. Clin Cancer Res 2006;12:5242-7. [PMID: 16951244 DOI: 10.1158/1078-0432.ccr-06-0688] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
131
Lorraine J, Lee B. A Canadian observational study of the optimal method of transition from postmenopausal hormone therapy to raloxifene. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA 2006;28:583-594. [PMID: 16916481 DOI: 10.1016/s1701-2163(16)32203-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
132
O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MAB, Grigg R, Jordan VC. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin Cancer Res 2006;12:2255-63. [PMID: 16609042 DOI: 10.1158/1078-0432.ccr-05-2584] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
133
Wang XN, Simmons HA, Salatto CT, Cosgrove PG, Thompson DD. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor β and androgen receptor in rats. Menopause 2006;13:609-20. [PMID: 16837883 DOI: 10.1097/01.gme.0000227337.73738.c9] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
134
Zhang L, Sinha V, Forgue ST, Callies S, Ni L, Peck R, Allerheiligen SRB. Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 2006;33:369-93. [PMID: 16770528 DOI: 10.1007/s10928-006-9010-8] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2005] [Accepted: 02/14/2006] [Indexed: 10/24/2022]
135
Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH. Adherence and Persistence Associated with the Pharmacologic Treatment of Osteoporosis in a Managed Care Setting. South Med J 2006;99:570-5. [PMID: 16800411 DOI: 10.1097/01.smj.0000221637.90495.66] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
136
Das JR, Fryar EB, Epie NN, Southerland WM, Bowen D. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate. Anticancer Res 2006;26:1877-83. [PMID: 16827120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
137
McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006;13:377-86. [PMID: 16735934 DOI: 10.1097/01.gme.0000188736.69617.4f] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
138
Fryar EB, Das JR, Davis JH, Desoto JA, Laniyan I, Southerland WM, Bowen D. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy. Anticancer Res 2006;26:1861-7. [PMID: 16827118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
139
Kokiko ON, Murashov AK, Hoane MR. Administration of raloxifene reduces sensorimotor and working memory deficits following traumatic brain injury. Behav Brain Res 2006;170:233-40. [PMID: 16580743 DOI: 10.1016/j.bbr.2006.02.026] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2005] [Revised: 01/24/2006] [Accepted: 02/20/2006] [Indexed: 11/29/2022]
140
Simorre B. 41e Congrès de l'EASD (European Association for The Study of Diabetes), 10–15 septembre 2005, Athènes, Grèce. Rev Med Interne 2006;27:356-7. [PMID: 16703668 DOI: 10.1016/j.revmed.2005.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
141
Christodoulakos GE, Botsis DS, Lambrinoudaki IV, Papagianni VD, Panoulis CP, Creatsa MG, Alexandrou AP, Augoulea AD, Dendrinos SG, Creatsas GC. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas 2006;53:413-23. [PMID: 16140483 DOI: 10.1016/j.maturitas.2005.07.003] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2005] [Revised: 06/13/2005] [Accepted: 07/07/2005] [Indexed: 10/25/2022]
142
Michalská D, Stepan JJ, Basson BR, Pavo I. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2006;91:870-7. [PMID: 16352692 DOI: 10.1210/jc.2004-2212] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
143
Hussain SA, Williams S, Stevens A, Rea DW. Endocrine therapy for early breast cancer. Expert Rev Anticancer Ther 2006;4:877-88. [PMID: 15485321 DOI: 10.1586/14737140.4.5.877] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
144
Trémollières F, Ribot C. [Raloxifene in postmenopausal women]. GYNECOLOGIE, OBSTETRIQUE & FERTILITE 2006;34:147-53. [PMID: 16483822 DOI: 10.1016/j.gyobfe.2005.12.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2005] [Accepted: 12/15/2005] [Indexed: 05/06/2023]
145
Murase Y, Kobayashi J, Asano A, Yamaaki N, Yonezawa K, Muramoto H, Mabuchi H. Effects of raloxifene on adipocytokines in Japanese osteoporotic postmenopausal women with and without type 2 diabetes. Horm Metab Res 2006;38:130-3. [PMID: 16523415 DOI: 10.1055/s-2006-925140] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
146
Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006;53:252-9. [PMID: 15990257 DOI: 10.1016/j.maturitas.2005.05.006] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2004] [Revised: 04/29/2005] [Accepted: 05/17/2005] [Indexed: 11/18/2022]
147
Mok CC, To CH, Mak A, Ma KM. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. ACTA ACUST UNITED AC 2006;52:3997-4002. [PMID: 16320346 DOI: 10.1002/art.21477] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
148
Kozakiewicz K, Wycisk A. [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease]. WIADOMOSCI LEKARSKIE (WARSAW, POLAND : 1960) 2006;59:377-82. [PMID: 17017486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
149
Stürmer EK, Seidlová-Wuttke D, Sehmisch S, Rack T, Wille J, Frosch KH, Wuttke W, Stürmer KM. Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene. J Bone Miner Res 2006;21:89-96. [PMID: 16355277 DOI: 10.1359/jbmr.050913] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/22/2005] [Revised: 09/01/2005] [Accepted: 09/26/2005] [Indexed: 11/18/2022]
150
Miki T, Saito S. [Bisphosphonate or Raloxifene?: which drug we can choose for osteoporotic patients?]. CLINICAL CALCIUM 2006;16:167-174. [PMID: 16397368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
PrevPage 6 of 12 125671112Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA